文献速递生殖医学

卵巢储备检测:使用者指南

Ovarian reserve testing: a user's guide.
PubMed 文献 · Am J Obstet Gynecol · 2017-02-21

本文综述卵巢储备检测的最新进展,为妇产科通科医生和生殖内分泌医生提供指导。理想的卵巢储备检测应便捷、可重复、周期内和周期间变异小、特异性高。目前尚无完美检测,但窦卵泡计数和抗苗勒管激素预测价值良好,优于第3天卵泡刺激素;抗苗勒管激素因采样不受时间限制、有年龄特异性值、自动化平台和潜在标准化而成为首选生物标志物。

要点

  • 窦卵泡计数和抗苗勒管激素预测价值良好,优于第3天卵泡刺激素。
  • 抗苗勒管激素因采样不受时间限制、有年龄特异性值、自动化平台和潜在标准化而成为首选生物标志物。
  • 卵巢储备检测可帮助识别对卵巢刺激反应不良或高反应的患者,并辅助个体化治疗方案。

核心结论

  • 目前尚无完美的卵巢储备检测,但窦卵泡计数和抗苗勒管激素预测价值良好,优于第3天卵泡刺激素。
  • 抗苗勒管激素因采样不受时间限制、有年龄特异性值、自动化平台和潜在标准化而成为女性卵巢储备评估的首选生物标志物。

研究设计与样本

  • 本文为综述,旨在总结卵巢储备检测的最新进展,为妇产科通科医生和生殖内分泌医生提供指导。

主要发现

  • 卵巢储备是受年龄、遗传和环境变量影响的复杂临床现象,预测个体卵巢储备下降速率具有挑战性。
  • 理想的卵巢储备检测应便捷、可重复、周期内和周期间变异小、特异性高,以降低误诊卵巢储备减退的风险并准确识别促排卵治疗前卵巢过度刺激高风险者。
  • 卵巢储备评估可帮助识别对辅助生殖技术卵巢刺激反应不良或高反应的患者,并实现治疗方案的个体化以优化反应同时最小化安全风险。
  • 卵巢储备检测可告知患者其生殖寿命和绝经时间,并辅助接受性腺毒性治疗的育龄女性癌症患者的咨询和治疗选择。
  • 卵巢储备检测还可辅助多囊卵巢综合征的诊断并提供其严重程度的见解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ovarian reserve is a complex clinical phenomenon influenced by age, genetics, and environmental variables. Although it is challenging to predict the rate of an individual's ovarian reserve decline, clinicians are often asked for advice about fertility potential and/or recommendations regarding the pursuit of fertility treatment options. The purpose of this review is to summarize the state-of-the-art of ovarian reserve testing, providing a guide for the obstetrician/gynecologist generalist and reproductive endocrinologist. The ideal ovarian reserve test should be convenient, be reproducible, display little if any intracycle and intercycle variability, and demonstrate high specificity to minimize the risk of wrongly diagnosing women as having diminished ovarian reserve and accurately identify those at greatest risk of developing ovarian hyperstimulation prior to fertility treatment. Evaluation of ovarian reserve can help to identify patients who will have poor response or hyperresponse to ovarian stimulation for assisted reproductive technology. Ovarian reserve testing should allow individualization of treatment protocols to achieve optimal response while minimizing safety risks. Ovarian reserve testing may inform patients regarding their reproductive lifespan and menopausal timing as well as aid in the counselling and selection of treatment for female cancer patients of reproductive age who receive gonadotoxic therapy. In addition, it may aid in establishing the diagnosis of polycystic ovary syndrome and provide insight into its severity. While there is currently no perfect ovarian reserve test, both antral follicular count and antimüllerian hormone have good predictive value and are superior to day-3 follicle-stimulating hormone. The convenience of untimed sampling, age-specific values, availability of an automated platform, and potential standardization of antimüllerian hormone assay make this test the preferred biomarker for the evaluation of ovarian reserve in women.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Tal R, Seifer DB. Ovarian reserve testing: a user's guide. Am J Obstet Gynecol. 2017. PMID: 28235465. doi:10.1016/j.ajog.2017.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。